tcsc0676 Tonabersat

Tonabersat is a gap-junction modulator.

IC50 & Target: Gap-junction^[1]

In Vitro: Tonabersat, a novel benzopyran derivative, inhibits cortical spreading depression (CSD) and therefore might be able to inhibit the early migraine mechanisms^[1].

In Vivo: Treatment with either Tonabersat (10 mg/kg) or Meclofenamate (20 mg/kg) as single agents significantly inhibit progression of metastatic lesions. Addition of carboplatin to either agent profoundly inhibits brain metastasis^[2].